Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis

Talissa A. Altes, Mac Johnson, Meredith C. Fidler, Martyn C. Botfield, Nicholas J. Tustison, Carlos Leiva‐Salinas, Eduard E. de Lange, Deborah Froh, John P. MuglerJournal of Cystic Fibrosis 2017 · DOI

Abstract

TVD responded to ivacaftor therapy. <sup>3</sup>He-MRI provides an individual quantification of disease burden that may be able to detect aspects of the disease missed by population-based spirometry metrics. Assessments by human reader and computer algorithm exhibit similar trends, but the latter appears more sensitive. www.clinicaltrials.gov identifier: NCT01161537.
BibTeX
@article{altes2017use,
  author = {Talissa A. Altes and Mac Johnson and Meredith C. Fidler and Martyn C. Botfield and Nicholas J. Tustison and Carlos Leiva‐Salinas and Eduard E. de Lange and Deborah Froh and John P. Mugler},
  title = {{Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis}},
  journal = {Journal of Cystic Fibrosis},
  year = {2017},
  doi = {10.1016/j.jcf.2016.12.004},
}

Loading related content...

Figure